NUCLEAR POWER IN BELARUS AND WORLDWIDE
MINSK, 16 June (BelTA) - Belarus will be able to almost completely meet the domestic market demand for anticancer drugs after the launch of a new production at Belmedpreparaty, Deputy Prime Minister Igor Petrishenko told the media during a visit to the company on 16 June, BelTA has learned.
“This is a new production of very important anticancer drugs. First of all, it is important to meet the needs of the domestic market. Thus, we will almost reach 100% in the domestic need for anticancer drugs,” said Igor Petrishenko.
The investment project to set up a pilot production of oral anticancer drugs in the version of isolating technologies will also help increase the company's export supplies. The total investment costs of the project amounted to Br31.9 million. Qualification and validation works are carried out this year. Plans are in place to conduct an audit to obtain the GMP certificate.
“The production is new and modern. A selection of highly qualified personnel is underway. Similar lines have been installed at the Borisov Plant of Medical Preparations, which, using advanced technologies, makes products important for the domestic and foreign markets,” the deputy prime minister said.
According to him, in setting up a new production of anticancer drugs and other productions, it is important to comply with GMP standards to have access to markets of other countries. Belmedpreparaty has registered 335 medicines in the domestic market, has more than 600 registration certificates of medicines in 20 countries.
“It is necessary to increase exports. Each pharmaceutical enterprise should supply some 50% of products abroad. This will mean good salaries, labor productivity and profit. Additional funds can and should be invested to re-equip production areas and master the new nomenclature that healthcare needs,” Igor Petrishenko said.
Belmedpreparaty is a part of Belpharmprom Holding Company and is one of the GDP-forming enterprises in the pharmaceutical industry. The enterprise has a number of unique production facilities and is the only Belarusian manufacturer of insulin preparations, including genetically engineered human insulin, enzyme and biogenic preparations, eye drops medicines for ophthalmology. The company produces almost all types of dosage forms.
About 38% of the output is sold on foreign markets. The geography of supplies includes 24 countries. The main markets are Russia, Ukraine, Kazakhstan, Azerbaijan, Uzbekistan, Kyrgyzstan and Vietnam.
The main areas of investment activity of Belmedpreparaty through 2025 will be further modernization and technical re-equipment of the production, fitting production shops with high-tech equipment, development of new production areas meeting GMP standards.
Photos by Oksana Manchuk
